<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03935204</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-PRO-008</org_study_id>
    <nct_id>NCT03935204</nct_id>
  </id_info>
  <brief_title>Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)</brief_title>
  <official_title>An Randomized, Double-Blinded, Placebo Controlled Phase II Clinical Trial to Estimate Immunogenicity of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Adults Aged 18 to 45 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiamen Innovax Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II clinical study was designed to evaluate the immunogenicity and safety of&#xD;
      Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli)(hereafter&#xD;
      called HPV vaccine), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy adults aged&#xD;
      18-45 years old.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific neutralizing antibody)</measure>
    <time_frame>month 7</time_frame>
    <description>To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing antibody level on day 0 (before the 1st dose) and one month after dose 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited local adverse reactions</measure>
    <time_frame>During the 7-day (Day 0-6) period following each vaccination</time_frame>
    <description>Solicited local adverse reactions occurred within 7 days after each vaccination;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited systematic adverse reactions</measure>
    <time_frame>During the 7-day (Day 0-6) period following each vaccination</time_frame>
    <description>Solicited systematic adverse reactions occurred within 7 days after each vaccination;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unsolicited adverse events</measure>
    <time_frame>Within 30 days (Day 0-29) after any vaccination</time_frame>
    <description>Unsolicited adverse reactions occurred within 30 days after each vaccination;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>throughout the study period, an average of 7 months</time_frame>
    <description>Serious adverse events occurred throughout the study;</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations at Months 7 (type specific IgG antibody)</measure>
    <time_frame>month 7</time_frame>
    <description>To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific IgG antibody level on day 0 (before the 1st dose) and one month after dose 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion rates and geometric mean concentrations in a immunogenicity subgroup at Months 1,2 and 7 (type specific neutralizing antibody and IgG antibody)</measure>
    <time_frame>month 1,2 and 6</time_frame>
    <description>To detect the anti-HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 type specific neutralizing and IgG antibody level of a immunogenicity subgroup at month 1,2 and 6.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">627</enrollment>
  <condition>Condylomata Acuminata</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>HPV Vaccine,270μg/1.0ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm would receive 270μg/1.0ml HPV vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm would receive 1.0ml aluminium adjuvant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV Vaccine,270μg/1.0ml</intervention_name>
    <description>HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.</description>
    <arm_group_label>HPV Vaccine,270μg/1.0ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Aluminium adjuvant (1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>aluminium adjuvant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Health women aged between 18 and 45 years.&#xD;
&#xD;
          2. Judged as healthy and eligible for vaccination by the investigators through a&#xD;
             self-reported medical history and some physical examinations.&#xD;
&#xD;
          3. Able to comply with the requests of the study.&#xD;
&#xD;
          4. Written informed consent obtained from the participants.&#xD;
&#xD;
          5. Axillary temperature not higher than 37.0°C&#xD;
&#xD;
          6. Non-pregnant women verified by a urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding or plan to be pregnant within 7 months.&#xD;
&#xD;
          2. Use of any investigational product or non-registered product (drug or vaccine) within&#xD;
             30 days preceding the first dose of the study vaccine or plan to use during the study&#xD;
             period.&#xD;
&#xD;
          3. Received immunosuppressed, immunoregulation therapy or corticosteroid systemic therapy&#xD;
             for more than 14 days in the 6 months before entry, except local treatment.&#xD;
&#xD;
          4. Administration of any immunoglobulin or blood products within 3 months preceding the&#xD;
             first dose of the study vaccine or plan to use within 7 months.&#xD;
&#xD;
          5. Administration of any attenuated live vaccines within 21 days preceding the first dose&#xD;
             of the study vaccine or any subunit or inactivated vaccines within 14 days before&#xD;
             vaccination.&#xD;
&#xD;
          6. Had a fever (axillary temperature over 38°C) within 3 days or acute illness requiring&#xD;
             systemic antibiotics or antiviral treatment within 5 days before vaccination.&#xD;
&#xD;
          7. Having the plan to participate another clinical trial during the study period.&#xD;
&#xD;
          8. Received another HPV vaccine.&#xD;
&#xD;
          9. Immunodeficiency , primary disease of important organs, malignant tumor, or any immune&#xD;
             disease (such as systemic lupus erythematosus, arthritis pauperum, splenectomy or&#xD;
             functional asplenia or other disease which might affect immune response).&#xD;
&#xD;
         10. History of allergic disease or history of serious adverse events occurring after&#xD;
             vaccination, i.e., allergy, urticaria, dyspnea, angioneurotic edema or abdominal pain.&#xD;
&#xD;
         11. Asthma that required emergent treatment, hospitalization, oral or intravenous&#xD;
             corticosteroid for unstable condition within the past 2 years.&#xD;
&#xD;
         12. Having serious disease of internal medicine, such as hypertension, cardiac disease,&#xD;
             diabetes, hyperthyroidism et al.&#xD;
&#xD;
         13. Diagnosed coagulant function abnormality or blood coagulation disorder.&#xD;
&#xD;
         14. Epilepsy, except fever epilepsy at under 2 years of age, alcohol-induced epilepsy in 3&#xD;
             years before abstinence, or idiopathic epilepsy requiring no treatment in the past 3&#xD;
             years.&#xD;
&#xD;
         15. Past or current two-stage affective psychosis, not well controlled in the past 2 years&#xD;
             or requiring drugs, or hve a tendency to commit suicide in the past 5 years.&#xD;
&#xD;
         16. Other medical, psychological, social or occupational factors that, according to the&#xD;
             investigators' judgment, might affect the individual's ability to obey the protocol or&#xD;
             sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhang, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Xiamen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yue-Mei Hu, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Centre for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial Centre for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xiamen University</investigator_affiliation>
    <investigator_full_name>Jun Zhang</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>human papillomavirus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

